Diagnostic company Exact Sciences Corporation (NASDAQ: EXAS) will be reporting earnings this Wednesday after market close. Here’s what to expect.
Exact Sciences beat analysts’ revenue expectations by 2.7% last quarter, reporting revenues of $706.8 million, up 10.9% year on year. It was a satisfactory quarter for the company, with full-year revenue guidance slightly topping analysts’ expectations but a significant miss of analysts’ EPS estimates.
Is Exact Sciences a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Exact Sciences’s revenue to grow 10.6% year on year to $773.1 million, slowing from the 12.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.05 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Exact Sciences has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 1.7% on average.
Looking at Exact Sciences’s peers in the biotechnology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Regeneron delivered year-on-year revenue growth of 3.6%, beating analysts’ expectations by 11.3%, and Incyte reported revenues up 16.5%, topping estimates by 5.5%. Regeneron traded up 4.8% following the results while Incyte was also up 10.5%.
Read our full analysis of Regeneron’s results here and Incyte’s results here.
Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the biotechnology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. Exact Sciences is down 9.1% during the same time and is heading into earnings with an average analyst price target of $68.55 (compared to the current share price of $47.70).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
